Tranzyme (TZYM) Drops After Disappointing ULISES 007 Trial Results
Posted on March 12, 2012 at 08:25 AM EDT
Tranzyme Inc. (NASDAQ:TZYM), a clinical-stage bio-pharmaceutical company, said the preliminary analysis of its ULISES 007 pivotal trial evaluating ulimorelin indicated study failed to meet its primary and secondary efficacy endpoints, sending its shares 70.59% lower in premarket trading. [More...]